{"title":"更正“avelumab联合吉西他滨作为二线治疗晚期平滑肌肉瘤的2期试验（EAGLES，韩国癌症研究组UN18-06）”","authors":"","doi":"10.1002/cncr.35777","DOIUrl":null,"url":null,"abstract":"<p>Kim M, Kim YJ, Suh KJ, et al. Phase 2 trial of avelumab in combination with gemcitabine in advanced leiomyosarcoma as a second-line treatment (EAGLES, Korean Cancer Study Group UN18-06). <i>Cancer.</i> 2025;131(1):e35609. doi:10.1002/cncr.35609</p><p>In the original title of the article, the Korean Cancer Study Group clinical trial number was incorrectly listed as “UN18-09.” The correct clinical trial number is “UN1806.”</p><p>The authors apologize for this error.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 6","pages":""},"PeriodicalIF":5.1000,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35777","citationCount":"0","resultStr":"{\"title\":\"Correction to “Phase 2 trial of avelumab in combination with gemcitabine in advanced leiomyosarcoma as a second-line treatment (EAGLES, Korean Cancer Study Group UN18-06)”\",\"authors\":\"\",\"doi\":\"10.1002/cncr.35777\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Kim M, Kim YJ, Suh KJ, et al. Phase 2 trial of avelumab in combination with gemcitabine in advanced leiomyosarcoma as a second-line treatment (EAGLES, Korean Cancer Study Group UN18-06). <i>Cancer.</i> 2025;131(1):e35609. doi:10.1002/cncr.35609</p><p>In the original title of the article, the Korean Cancer Study Group clinical trial number was incorrectly listed as “UN18-09.” The correct clinical trial number is “UN1806.”</p><p>The authors apologize for this error.</p>\",\"PeriodicalId\":138,\"journal\":{\"name\":\"Cancer\",\"volume\":\"131 6\",\"pages\":\"\"},\"PeriodicalIF\":5.1000,\"publicationDate\":\"2025-03-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35777\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cncr.35777\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cncr.35777","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Correction to “Phase 2 trial of avelumab in combination with gemcitabine in advanced leiomyosarcoma as a second-line treatment (EAGLES, Korean Cancer Study Group UN18-06)”
Kim M, Kim YJ, Suh KJ, et al. Phase 2 trial of avelumab in combination with gemcitabine in advanced leiomyosarcoma as a second-line treatment (EAGLES, Korean Cancer Study Group UN18-06). Cancer. 2025;131(1):e35609. doi:10.1002/cncr.35609
In the original title of the article, the Korean Cancer Study Group clinical trial number was incorrectly listed as “UN18-09.” The correct clinical trial number is “UN1806.”
期刊介绍：
The CANCER site is a full-text, electronic implementation of CANCER, an Interdisciplinary International Journal of the American Cancer Society, and CANCER CYTOPATHOLOGY, a Journal of the American Cancer Society.
CANCER publishes interdisciplinary oncologic information according to, but not limited to, the following disease sites and disciplines: blood/bone marrow; breast disease; endocrine disorders; epidemiology; gastrointestinal tract; genitourinary disease; gynecologic oncology; head and neck disease; hepatobiliary tract; integrated medicine; lung disease; medical oncology; neuro-oncology; pathology radiation oncology; translational research
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
